Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05326542
Other study ID # ECLIPSE20220312
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date September 2022
Est. completion date December 2022

Study information

Verified date September 2022
Source Changhai Hospital
Contact Liang-hao Hu, MD
Phone +86-13817593520
Email ianghao-hu@smmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will compare the efficacy of ESWL and Laser Lithotripsy in the treatment of pancreatic duct stones with ERCP.


Description:

Chronic pancreatitis (CP) is an inflammatory disease that can causes progressive fibrosis of pancreatic tissue and eventually leads to damage of pancreatic exocrine and endocrine. According to statistics, the prevalence of CP in China is 13/10 million, which is still increasing. Pancreatic duct stones are the most important pathological changes of CP. More than 50% of patients with CP are accompanied by pancreatic duct stones, which can lead to pancreatic duct obstruction, hypertension and tissue ischemia. Removal of pancreatic duct stones under Endoscopic Retrograde Cholangiopancreatography (ERCP) are the first choice. ERCP is effective in the treatment of pancreatic duct stones by using basket and/or balloon catheter. But in most cases, ERCP is only suitable for the treatment of pancreatic duct stones (diameter < 5mm) located in the head/body of the Pancreatic Duct (PD). PD stones larger than 5mm generally require Extracorporeal Shock Wave Lithotripsy (ESWL) or Endoscopic Intraductal Lithotripsy (EIL) for pretreatment. EIL includes Electrohydraulic Lithotripsy (EHL) and Laser Lithotripsy (LL). ESWL first locates the stone by X-ray, and then uses an electromagnetic pulse generator to direct a higher-energy shock wave to the stone, so that the stone is crushed by thousands of shock waves. The principle of laser lithotripsy is to make the stone absorb strong infrared rays and generate shock waves to achieve the purpose of fragmenting the stone. In view of the fact that there is no relevant research comparing the overall efficacy of ESWL combined with ERCP and EIL combined with ERCP, it is necessary to evaluate the differences in the therapeutic effects and complications of the two for PD stones. This research helps to provide evidence-based medical evidence, guide physicians' clinical practice, improve the quality of patients' lives, and reduce the economic burden of patients.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date December 2022
Est. primary completion date October 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - symptomatic adult patients diagnosed with chronic pancreatitis and pancreatic duct stones; - at least one stone (>5 mm in diameter) located in the pancreatic duct of the head/body of the pancreas; - dilation of the proximal pancreatic duct. Exclusion Criteria: - history of ERCP or ESWL treatment; - suspected to have malignant tumors; - history of pancreatic surgery or gastrojejunostomy (Billroth II); - pancreatic pseudocyst with a diameter >4cm; - bile duct stricture secondary to cholangitis or chronic pancreatitis; - acute pancreatitis exacerbation or acute exacerbation of chronic pancreatitis (including biliary pancreatitis); - coagulation dysfunction (INR=1.5 or platelet count=50×10^9/L); - pregnant or breastfeeding women; - patients who refused to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
ESWL and ERCP
First, ESWL will be used for lithotripsy, and then ERCP will be performed to clear the stones after lithotripsy.
LL and ERCP
After establishing the working channel under ERCP, the stone will be crushed with a laser lithotripter, and then ERCP will clear the stones after lithotripsy.

Locations

Country Name City State
China Changhai Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Changhai Hospital

Country where clinical trial is conducted

China, 

References & Publications (1)

Hao L, Liu Y, Xie T, Wang T, Guo HL, Pan J, Wang D, Bi YW, Ji JT, Xin L, Du TT, Lin JH, Zhang D, Zeng XP, Zou WB, Chen H, Li BR, Liao Z, Cong ZJ, Shi RH, Li ZS, Hu LH. Risk Factors and Nomogram for Pancreatic Stone Formation in Chronic Pancreatitis over a Long-Term Course: A Cohort of 2,153 Patients. Digestion. 2020;101(4):473-483. doi: 10.1159/000500941. Epub 2019 Jun 25. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other abdominal pain relief rate Postoperative and preoperative abdominal pain was assessed using the Visual Analogue Scale (VAS). VAS can be calculated ranging from 0 (no pain) to 100 (severe pain). 30 days after ERCP procedure
Primary technical success rates Technical success rates refer to the successful completion of standard procedures or the occurrence of complete spontaneous stone removal. during ERCP procedure
Primary clearance rates of pancreatic duct stones Clearance rates have been defined as complete, partial, or failure if the proportion of stones cleared was > 90%, 50% - 90%, or < 50%, respectively. during ERCP procedure
Secondary time taken to completely clear the stone The time taken to completely clear the stones. during ESWL and ERCP procedure
Secondary postoperative complications Major post-ERCP complications includes post-ERCP pancreatitis, bleeding, infection, and perforation, which are classified as mild, moderate, or severe, depending mainly on the length of hospitalization and the need for invasive treatment. 30 days after ERCP procedure
Secondary success rates of pancreatic duct decompression Successful removal of pancreatic duct obstruction factors by clearing stones and/or placing pancreatic duct stents/nasopancreatic catheters. during ERCP procedure
See also
  Status Clinical Trial Phase
Completed NCT01551511 - Δ9-THC (Namisol®) in Chronic Pancreatitis Patients Suffering From Persistent Abdominal Pain Phase 2
Completed NCT01731821 - Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Phase 3
Active, not recruiting NCT05095831 - EUS Shear Wave for Solid Pancreatic Lesions.
Completed NCT03173118 - Elastography in the Diagnosis of Chronic Pancreatitis N/A
Terminated NCT01318590 - Prospective Study on Endoscopic Ultrasound (EUS) Celiac Bloc Efficacy in Chronic Pancreatitis Phase 3
Recruiting NCT05772234 - Aggressive Intravenous Hydration With Lactated Ringer's Solution for Prevention of Post-ESWL Pancreatitis N/A
Recruiting NCT04131010 - Digital Catheter Based Pancreatoscopy (SpyGlassDS) for the Management of Symptomatic Pancreatic Duct Stones in Selected Patients With Chronic Pancreatitis N/A
Terminated NCT00359320 - A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy N/A
Completed NCT02940067 - Enhancing Fitness Before Pancreatic Surgery N/A
Recruiting NCT05261997 - Endotherapy for Painless Chronic Pancreatitis N/A
Not yet recruiting NCT05270434 - Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis. N/A
Completed NCT03672422 - Pediatric Longitudinal Cohort Study of Chronic Pancreatitis
Enrolling by invitation NCT05287737 - Clinical Outcome After Total Pancreatectomy With Islet Autotransplantation
Not yet recruiting NCT06426160 - Tocilizumab for Painful Chronic Pancreatitis Phase 2
Enrolling by invitation NCT05289362 - Comparison of Efficacy of Basket and Balloon in the Removal of Pancreatic Duct Stones in Chronic Pancreatitis Under ERCP N/A
Not yet recruiting NCT04760847 - Intermittent Fasting for Pancreatitis N/A
Enrolling by invitation NCT03228095 - Volatiles in Breath and Headspace Analysis - Diagnostic Markers
Completed NCT00956839 - Prospective Study of Efficacy of Intra-muscular Vitamin D3 in Tropical Calcific Pancreatitis Phase 4
Completed NCT00676702 - A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI) Phase 1
Recruiting NCT04672642 - Evaluation of the SpyGlass DS for Detection of Residual Pancreatic Calculations N/A